In the Basque Country in northern Spain, just before the Civil War, three men in dinner suits stop for a drink at a bar before continuing on their way to a wedding. Their trip is interrupted when their leader, the wealthy Don Leopoldo, has a stroke in the restroom.This event, bizarre and undignified though it is, begins to weave together the lives of two remarkable women: the bride, the beautiful and distinguished Isabel Cruces, and María Antonia Etxarri, the bar owner’s adolescent daughter. Shortly after the outbreak of the war, María Antonia is raped and Isabel’s newlywed husband, Captain Julen Herraiz, is shot. Both women find themselves violently altered, alone, and pregnant. A crippled but wise local doctor is the only witness to the mysterious, silent agreement these women conclude in the loneliness and desperation of their mutual suffering. Many years later, a young student, grandson to Isabel, returns to the scene of the events to spend an innocent summer studying for law exams. As he goes about his work, he unwittingly awakens the ghosts haunting both María Antonia and the doctor, and through their memories the passionate stories of the past unfurl before the reader. De Lope brilliantly reveals his incredible story through flashes of memory and emotion, told in a winding torrent that expresses the cumulative nature of both history and nostalgia.

NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close. “Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.

"Excellent…Tucker’s chronicle of the world of 17th-century science in London and Paris is fascinating." —The Economist In December 1667, maverick physician Jean Denis transfused calf’s blood into one of Paris’s most notorious madmen. Days later, the madman was dead and Denis was framed for murder. A riveting exposé of the fierce debates, deadly politics, and cutthroat rivalries behind the first transfusion experiments, Blood Work takes us from dissection rooms in palaces to the streets of Paris, providing an unforgettable portrait of an era that wrestled with the same questions about morality and experimentation that haunt medical science today.

"Blood transfusion is a life-saving intervention that has an essential role in patient management within health care systems. All Member States of the World Health Organization (WHO) endorsed World Health Assembly resolutions WHA28.72 (1) in 1975 and WHA58.13 (2) in 2005. These commit them to the provision of adequate supplies of safe blood and blood products that are accessible to all patients who require transfusion either to save their lives or promote their continuing or improving health." --Preface.

Animals and Medicine: The Contribution of Animal Experiments to the Control of Disease offers a detailed, scholarly historical review of the critical role animal experiments have played in advancing medical knowledge. Laboratory animals have been essential to this progress, and the knowledge gained has saved countless lives—both human and animal. Unfortunately, those opposed to using animals in research have often employed doctored evidence to suggest that the practice has impeded medical progress. This volume presents the articles Jack Botting wrote for the Research Defence Society News from 1991 to 1996, papers which provided scientists with the information needed to rebut such claims. Collected, they can now reach a wider readership interested in understanding the part of animal experiments in the history of medicine—from the discovery of key vaccines to the advancement of research on a range of diseases, among them hypertension, kidney failure and cancer.This book is essential reading for anyone curious about the role of animal experimentation in the history of science from the nineteenth century to the present.

During the early years of the AIDS epidemic, thousands of Americans became infected with HIV through the nation's blood supply. Because little reliable information existed at the time AIDS first began showing up in hemophiliacs and in others who had received transfusions, experts disagreed about whether blood and blood products could transmit the disease. During this period of great uncertainty, decision-making regarding the blood supply became increasingly difficult and fraught with risk. This volume provides a balanced inquiry into the blood safety controversy, which involves private sexual practices, personal tragedy for the victims of HIV/AIDS, and public confidence in America's blood services system. The book focuses on critical decisions as information about the danger to the blood supply emerged. The committee draws conclusions about what was doneâ€"and recommends what should be done to produce better outcomes in the face of future threats to blood safety. The committee frames its analysis around four critical area: Product treatmentâ€"Could effective methods for inactivating HIV in blood have been introduced sooner? Donor screening and referralâ€"including a review of screening to exlude high-risk individuals. Regulations and recall of contaminated bloodâ€"analyzing decisions by federal agencies and the private sector. Risk communicationâ€"examining whether infections could have been averted by better communication of the risks.